LOXL2 and Hepatic fibrosis: In addition to direct targeted LOX studies, inhibition of lysyl oxidase-like-2 (LOXL2) raised during hepatic fibrosis has also been shown to be effective in relieving hepatic fibrosis and promoting fibrosis reversal 84, 85.